Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer

Alexander Rolevich\(^1\), Alexander Minich\(^1\), Tatiana Nabebina\(^2\), Sergey Polyakov\(^1\), Sergey Krasny\(^1\), Oleg Sukonko\(^1\)

\(^1\)Department of Urology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus
\(^2\)Department of Pathology, N.N. Alexandrov National Cancer Centre, Minsk, Belarus

Article history
Submitted: Feb. 16, 2016
Accepted: March 23, 2016
Published online: April 19, 2016

Introduction
One of the factors responsible for the risk of recurrence after complete transurethral resection of the bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC) is the quality of surgery that may vary between individual surgeons. The aim of the study was to evaluate the impact of the surgeon on recurrence-free survival in patients with NMIBC.

Material and methods
The long-term results of a series of consecutive TURBTs performed by five staff urologists at a single institution were retrospectively analyzed. A total of 949 cases of organ-preserving treatment in 784 patients with NMIBC were included in the analysis.

Results
With the median follow-up of 64.3 months (3–124 months), the 5-year recurrence-free survival rates according to the surgeon were 62.9% (95% CI 56.2–69.7%), 53.6% (95% CI 47.4–59.9%), 51.0% (95% CI 39.6–62.4%), 46.2% (95% CI 36.4–56.0%), and 44.2% (95% CI 36.8–51.7%), respectively (p <0.0001). In the multivariate analysis including all potential risk factors, the individual surgeon was associated with a risk of recurrence with a high degree of statistical significance (p = 0.0013). The between-surgeon differences in the recurrence risk were not that pronounced in less extensive tumors.

Conclusions
A surgeon has a significant impact on the risk of recurrence after curative treatment of patients with NMIBC. This effect was observed despite the relatively extensive experience in bladder endoscopic surgery of all of the surgeons and practicing in a setting of one specialized center. These findings should be taken into account while performing and evaluating the results of comparative studies.

Key Words: non-muscle invasive bladder cancer • transurethral resection • quality of surgery
To mitigate the imbalance in prognostic variables or adjuvant therapy use between surgical groups, the uni- and multivariate Cox regression analyses were performed with adjustment to all potential prognostic factors. An explanatory analysis of the benefit of performing the surgical intervention by the two most successful surgeons as compared to the two least successful ones in various subgroups of patients was also conducted. The statistical calculations were done with the IBM SPSS V21.0. (Armonk, NY) software package.

RESULTS

The surgical groups were comparable with respect to age, gender, recurrence rate, T-stage, carcinoma in situ (CIS) rate, EORTC risk groups, and frequency of restaging TURBTs (Table 1). However, there were statistically significant differences between the surgical groups in the period of therapy (p < 0.0001), the number of tumors (p < 0.0001), the tumor grade (p = 0.043), and a trend for the differences in the tumor size (p = 0.065), and the use of the adjuvant intravesical BCG immunotherapy (p = 0.068).

The median follow-up time for the entire cohort was 64.3 months (range from 3 to 124 months), and for surgical groups 1–5: 64.3, 54.1, 72.4, 68.6, and 70.9, respectively. During this period, 433 (45.6%) recurrences were detected: 83 (36.9%), 136 (42.0%), 41 (52.6%), 59 (51.3%), and 114 (55.1%) in groups 1–5, respectively. The 5-year recurrence-free survival rates were 52.8% (95% CI 49.4–56.3%) for the entire cohort, and 62.9% (95% CI 56.2–69.7%), 53.6%, 41 (52.6%), 59 (51.3%), and 114 (55.1%) in groups 1–5, respectively. The 5-year recurrence-free survival rates were 52.8% (95% CI 49.4–56.3%) for the entire cohort, and 62.9% (95% CI 56.2–69.7%), 53.6%

![Figure 1. Recurrence-free survival by individual surgeon.](image-url)
(95% CI 47.4–59.9%), 51.0% (95% CI 39.6–62.4%), 46.2% (95% CI 36.4–56.0%), and 44.2% (95% CI 36.8–51.7%) for groups 1–5, respectively (p < 0.0001, Figure 1). In the subgroup with low or intermediate risk of recurrence the differences in the recurrence-free survival did not reach statistical significance (p = 0.36), however, in high-risk cases there were highly significant differences among the surgical groups (p < 0.0001, Figure 2).

In the univariate Cox regression analysis, the statistically significant association of risk of recurrence was observed for recurrent, multifocal tumors, high tumor grade, duration of the TURBT and the individual surgeon (Table 2). In the multivariate analysis including all potential risk factors, the association of the individual surgeon with the recurrence risk remained significantly high (p = 0.0013). Amongst other factors significantly associated with recurrence were recurrent tumor state, multifocality, and adjuvant intravesical therapy.

The assessment of recurrence risk for the two most successful surgeons compared to the two least

Table 1. Characteristics of the cases included

| Characteristic                  | Total          | Surgeon 1 | Surgeon 2 | Surgeon 3 | Surgeon 4 | Surgeon 5 | p   |
|--------------------------------|----------------|-----------|-----------|-----------|-----------|-----------|-----|
| Number of cases, n (%)         | 949 (100)      | 225 (100) | 324 (100) | 78 (100)  | 115 (100) | 207 (100) |     |
| Gender, n (%)                  |                |           |           |           |           |           |     |
| female                         | 210 (22.1)     | 43 (19.1) | 76 (23.5) | 17 (21.8) | 25 (21.7) | 49 (23.7) | 0.77|
| male                           | 739 (77.9)     | 182 (80.9)| 248 (76.5)| 61 (78.2) | 90 (78.3) | 158 (76.3)|     |
| Age, median (range)            | 67 (23-93)     | 69 (32-88)| 66 (23-93)| 65 (30-93)| 66 (35-87)| 65 (29-87)| 0.075|
| Year of surgery, n (%)         |                |           |           |           |           |           |     |
| 2004 – 07                      | 378 (39.8)     | 80 (35.6) | 112 (34.6)| 38 (48.7) | 55 (47.8) | 93 (44.9) | <0.0001|
| 2008 – 10                      | 317 (33.4)     | 113 (50.2)| 82 (25.3) | 32 (41.0) | 39 (33.9) | 51 (24.6) |     |
| 2011 – 13                      | 254 (26.8)     | 32 (14.2) | 130 (40.1)| 8 (10.3)  | 21 (18.3) | 63 (30.4) |     |
| Prior recurrence, n (%)        |                |           |           |           |           |           |     |
| primary                        | 605 (63.8)     | 149 (66.2)| 206 (63.6)| 47 (60.3) | 77 (67.0) | 126 (60.9)| 0.29|
| recurrent                      | 343 (36.1)     | 76 (33.8) | 118 (36.4)| 31 (39.7) | 37 (32.2) | 81 (39.1) |     |
| Number of tumors, n (%)        |                |           |           |           |           |           |     |
| 1                              | 385 (40.6)     | 106 (47.1)| 121 (37.3)| 35 (44.9) | 51 (44.3) | 72 (34.8) | <0.0001|
| 2-7                            | 438 (46.2)     | 72 (32.0) | 166 (51.2)| 35 (44.9) | 54 (47.0) | 111 (53.6)|     |
| ≥8                             | 126 (13.3)     | 47 (20.9) | 37 (11.4) | 8 (10.3)  | 10 (8.7)  | 24 (11.6) |     |
| Tumor size, n (%)              |                |           |           |           |           |           |     |
| <3 cm                          | 645 (68.0)     | 157 (69.8)| 205 (63.3)| 50 (64.1) | 74 (64.3) | 159 (76.8)| 0.065|
| ≥3 cm                          | 297 (31.3)     | 66 (29.3) | 117 (36.1)| 28 (35.9) | 39 (33.9) | 47 (22.7) |     |
| NA                             | 7 (0.7)        | 2 (0.9)   | 2 (0.6)   | –          | 2 (1.7)   | 1 (0.5)   |     |
| T category, n (%)              |                |           |           |           |           |           |     |
| Ta                             | 386 (40.7)     | 82 (36.4)| 138 (42.6)| 31 (39.7) | 50 (43.5) | 85 (41.1) | 0.63|
| T1                             | 563 (59.3)     | 143 (63.6)| 186 (57.4)| 47 (60.3) | 65 (56.5) | 122 (58.9)|     |
| Tumor grade, n (%)             |                |           |           |           |           |           |     |
| G1                             | 604 (63.6)     | 155 (68.9)| 187 (57.7)| 45 (57.7) | 81 (70.4) | 136 (65.7)| 0.043|
| G2                             | 266 (28.0)     | 50 (22.2) | 104 (32.1)| 30 (38.5) | 25 (21.7) | 57 (27.5) |     |
| G3                             | 57 (6.0)       | 14 (6.2)  | 27 (8.3)  | 1 (1.3)   | 5 (4.3)   | 10 (4.8)  |     |
| Gx                             | 22 (2.3)       | 6 (2.7)   | 6 (1.9)   | 2 (2.6)   | 4 (3.5)   | 4 (1.9)   |     |
| CIS, n (%)                     | 16 (1.7)       | 7 (3.1)   | 6 (1.9)   | –          | 1 (0.9)   | 2 (1.0)   | 0.26|
| EORTC risk group, n (%)        |                |           |           |           |           |           |     |
| low                            | 89 (9.4)       | 28 (12.4) | 23 (7.1)  | 7 (9.0)   | 13 (11.3) | 18 (8.7)  | 0.28|
| intermediate                   | 304 (32.0)     | 79 (35.1)| 98 (30.2)| 23 (29.5)| 38 (33.0) | 66 (31.9)| 0.28|
| high                           | 520 (54.8)     | 109 (48.4)| 194 (59.3)| 36 (58.5)| 56 (48.7) | 117 (56.5)|     |
| NA                             | 36 (3.8)       | 9 (4.0)   | 9 (2.8)   | 4 (5.1)   | 8 (7.0)   | 6 (2.9)   |     |
| Modified risk group *, n (%)   |                |           |           |           |           |           |     |
| low                            | 281 (29.6)     | 73 (32.4)| 89 (27.5)| 24 (30.8)| 45 (39.1)| 50 (24.2)| 0.052|
| intermediate                   | 429 (45.2)     | 109 (48.4)| 149 (46.0)| 34 (43.6)| 39 (33.9)| 98 (47.3)|     |
| high                           | 239 (25.2)     | 43 (19.1)| 86 (26.5)| 20 (25.6)| 31 (27.0)| 59 (28.5)|     |
| reTUR, n (%)                   | 41 (4.3)       | 13 (5.8)  | 16 (4.9)  | 4 (5.1)   | 5 (4.3)   | 3 (1.4)   | 0.22|
| Intravesical therapy, n (%)    |                |           |           |           |           |           |     |
| BCG chemotherapy               | 200 (21.1)     | 47 (20.9)| 79 (24.4)| 14 (17.9)| 21 (18.3)| 39 (18.8)| 0.068|
| chemotherapy                   | 10 (1.1)       | 6 (2.7)   | 1 (0.3)   | 2 (2.6)   | –          | 1 (0.5)   |     |

n – number of cases; NA – data not available; CIS – carcinoma in situ; EORTC – European Organisation for Research and Treatment of Cancer; BCG – bacillus Calmette–Guérin; reTUR – restaging transurethral resection; * low risk – primary solitary tumor, intermediate risk – recurrent or multifocal, high risk – recurrent and multifocal tumor
Central European Journal of Urology

Central European Journal of Urology

The publication by Brausi et al. [6], who assessed the variability in the early recurrence rate (i.e. identified at the first follow-up cystoscopy 3 months after the TURBT) between different urological clinics in the seven EORTC phase III trials including 2,410 patients with NMIBC. As a result, a significant variability was detected in the early recurrence rate which ranged from 3% to 21% for patients with a single tumor and from 7% to 46% for multiple tumors. It was stated that those differences could only be explained by the variability in the quality of the TURBT performed by individual surgeons, and a high rate of residual tumor after poor quality TURBT is responsible for high early recurrence rates.

Subsequent studies were focused on establishing the causes of this variability, identifying the criteria for the quality of TURBT, and finding ways to improve the thoroughness of the surgery. Later successful ones in different patient subgroups is shown in Figure 3. The maximum benefit from the surgical intervention performed by surgeons 1–2 was observed in more extensive cases (≥8 tumors, >3 cm, solid, T1, with high-risk of recurrence and without subsequent use of intravesical therapy). The results did not differ significantly in low-risk tumors. The distribution of early recurrence frequencies by the most and least successful surgeons stratified by the modified recurrence risk group (Table 3) showed that the most divergent figures without overlapping CIs were at 12 months after TURBT.

DISCUSSION

For many years, the cornerstone of recurrence prevention strategy in NMIBC patients was the use of intravesical instillation therapy. The quality of the surgical part of the treatment has come to the attention of the urological community after the publication by Brausi et al. [6], who assessed the variability in the early recurrence rate (i.e. identified at the first follow-up cystoscopy 3 months after the TURBT) between different urological clinics in the seven EORTC phase III trials including 2,410 patients with NMIBC. As a result, a significant variability was detected in the early recurrence rate which ranged from 3% to 21% for patients with a single tumor and from 7% to 46% for multiple tumors. It was stated that those differences could only be explained by the variability in the quality of the TURBT performed by individual surgeons, and a high rate of residual tumor after poor quality TURBT is responsible for high early recurrence rates.

Subsequent studies were focused on establishing the causes of this variability, identifying the criteria for the quality of TURBT, and finding ways to improve the thoroughness of the surgery. Later

Figure 2. Recurrence-free survival by individual surgeons in subgroups with low and intermediate risk of recurrence (a) and high risk of recurrence (b) by EORTC; S – surgeon.
In a retrospective study, Jacke et al. evaluated the impact of surgical experience on the recurrence and progression rates in 768 patients with primary NMIBC. They found a substantial decrease in the risk of recurrence after TURBTs performed in the EORTC quality control study on TURBT, Brausi et al. showed that after adjustment for prognostic factors the reduction in the recurrence rate was associated with the use of a bladder diagram and being a staff urologist rather than a resident or a chief [6, 7]. In a retrospective study, Jacke et al. evaluated the impact of surgical experience on the recurrence and progression rates in 768 patients with primary NMIBC. They found a substantial decrease in the risk of recurrence after TURBTs performed

Table 2. Results of uni- and multivariate Cox regression analyses

| Variable                  | Univariate analysis | Multivariate analysis |
|---------------------------|--------------------|----------------------|
|                           | HR (95% CI)        | p        | HR (95% CI)        | p        |
| Surgeon                   |                    |          |                    |          |
| surgeon 1                 | 1.0                | <0.0001  | 1.0                | 0.0013   |
| surgeon 2                 | 1.25 (0.95-1.64)   | 0.11     | 1.15 (0.85-1.56)   | 0.36     |
| surgeon 3                 | 1.59 (1.09-2.31)   | 0.016    | 1.42 (0.97-2.10)   | 0.075    |
| surgeon 4                 | 1.63 (1.17-2.28)   | 0.004    | 1.70 (1.19-2.41)   | 0.0033   |
| surgeon 5                 | 1.80 (1.35-2.39)   | <0.0001  | 1.71 (1.26-2.32)   | 0.0005   |
| Gender                    |                    |          |                    |          |
| female                    | 1.0                | —        | 1.0                | —        |
| male                      | 1.06 (0.84-1.33)   | 0.63     | 1.03 (0.82-1.30)   | 0.80     |
| Age                       |                    |          |                    |          |
| ≤65 years                 | 1.0                | —        | 1.0                | —        |
| >65 years                 | 1.06 (0.88-1.28)   | 0.55     | 1.03 (0.84-1.25)   | 0.79     |
| Year of surgery           |                    |          |                    |          |
| 2004 – 07                 | 1.0                | 0.54     | 1.0                | 0.53     |
| 2008 – 10                 | 1.01 (0.81-1.26)   | 0.94     | 0.94 (0.74-1.20)   | 0.63     |
| 2011 – 13                 | 1.14 (0.89-1.47)   | 0.30     | 1.11 (0.85-1.45)   | 0.45     |
| Prior recurrence          |                    |          |                    |          |
| primary                   | 1.0                | —        | 1.0                | —        |
| recurrent                 | 1.76 (1.46-2.13)   | <0.0001  | 1.90 (1.54-2.34)   | <0.0001  |
| Number of tumors          |                    |          |                    |          |
| 1                         | 1.0                | —        | 1.0                | —        |
| 2–7                       | 1.66 (1.34-2.05)   | <0.0001  | 1.57 (1.25-1.97)   | 0.0001   |
| ≥8                        | 1.95 (1.46-2.60)   | <0.0001  | 1.87 (1.33-2.61)   | 0.0003   |
| Tumor size                |                    |          |                    |          |
| <3 cm                     | 1.0                | —        | 1.0                | —        |
| ≥3 cm                     | 1.09 (0.89-1.33)   | 0.43     | 1.09 (0.85-1.39)   | 0.52     |
| Macroscopic tumor type    |                    |          |                    |          |
| papillary                 | 1.0                | —        | 1.0                | —        |
| solid                     | 1.22 (0.82-1.82)   | 0.32     | 1.29 (0.84-2.00)   | 0.25     |
| T category                |                    |          |                    |          |
| Ta                        | 1.0                | —        | 1.0                | —        |
| T1                        | 1.18 (0.97-1.44)   | 0.09     | 0.99 (0.8-1.22)    | 0.92     |
| Tumor grade               |                    |          |                    |          |
| G1                        | 1.0                | —        | 1.0                | —        |
| G2                        | 1.26 (1.02-1.56)   | 0.029    | 1.13 (0.90-1.43)   | 0.29     |
| G3                        | 1.37 (0.94-2.00)   | 0.10     | 1.35 (0.90-2.02)   | 0.15     |
| CIS                       |                    |          |                    |          |
| no                        | 1.0                | —        | 1.0                | —        |
| yes                       | 0.51 (0.21-1.22)   | 0.13     | 0.66 (0.24-1.78)   | 0.41     |
| Length of surgery         |                    |          |                    |          |
| ≤20 min                   | 1.0                | —        | 1.0                | —        |
| 21-30 min                 | 1.27 (1.01-1.60)   | 0.045    | 1.11 (0.85-1.43)   | 0.45     |
| 31-40 min                 | 1.21 (0.87-1.68)   | 0.26     | 1.06 (0.72-1.54)   | 0.78     |
| >40 min                   | 1.42 (1.10-1.83)   | 0.008    | 1.32 (0.94-1.87)   | 0.11     |
| reTUR                      |                    |          |                    |          |
| no                        | 1.0                | —        | 1.0                | —        |
| yes                       | 1.39 (0.91-2.12)   | 0.13     | 1.26 (0.80-2.00)   | 0.32     |
| Intravesical therapy      |                    |          |                    |          |
| no                        | 1.0                | —        | 1.0                | —        |
| yes                       | 0.84 (0.67-1.06)   | 0.15     | 0.64 (0.50-0.82)   | 0.0005   |

HR – hazard ratio; CI – confidence interval; CIS – carcinoma in situ; reTUR – restaging transurethral resection
In a similar study by Di Zingaro et al., which included 209 patients with intermediate and high risk NMIBC, found high surgical volume (defined as experience in more than 100 TURBTs) to be predictive for recurrence and progression [8].

In contrast to these studies, in our series, all the surgeons had a status of specialist and their experience in performing TURBT significantly exceeded 100 surgical interventions. Therefore, the differences in the long-term outcomes in our study cannot entirely be explained by the poor basic technique associated with the initial training period. In addition, we could not detect the presence of a significant learning curve. For example, the risk of recurrence did not differ significantly based on the year of a surgery in the multivariate analysis. Furthermore, the analysis of the recurrence-free survival by experience in TURBTs, categorized as <10 and ≥10 years, showed worse results with increased experience both among the most and least successful surgeons (Figure 4), which might reflect a relative increase in more advanced cases over time.

There are several possible explanations for these observations: despite the fact that the TURBT is considered a simple surgical intervention, the learning curve for providing the best results with this operation may significantly exceed 100 cases or 4–5 years of residency. Another explanation could be that some of the surgeons’ successes in achieving better results may be associated with certain inborn professional qualities (e.g. alertness, scrupulousness, etc.) and does not change substantially over time.

Meanwhile, these findings raise an important question on defining the quality of TURBT. In this regard, the mainstream idea was to consider the presence of muscle tissue in the specimen after TURBT as a key quality indicator of surgical completeness. As early as in 1999, Herr showed that this parameter predicted the rate of muscle-invasive disease after restaging TURBT in patients

![Figure 3](image)

**Figure 3.** Subgroup analysis of recurrence hazard ratio (HR) after transurethral resection (TUR) performed by the two most successful (1–2) surgeons as compared to the two least successful (4–5). CI – confidence interval; EORTC – European Organisation for Research and Treatment of Cancer; WHO – World Health Organisation.

**Table 3.** Recurrence rate in the first 3, 6, and 12 months after TUR performed by the two most and two least successful surgeons within different prognostic groups

| Subgroup                | Recurrence rate in 3 months | Recurrence rate in 6 months | Recurrence rate in 12 months |
|-------------------------|----------------------------|-----------------------------|----------------------------|
|                         | n / N (%)                  | 95%CI                       | n / N (%)                  | 95%CI                       |
| Primary solitary tumors |                            |                             |                            |
| Surgeons 1-2            | 2/162 (1.2)                | 0-3                         | 6/162 (3.7)                | 0.8-6.6                     |
| Surgeons 4-5            | 4/95 (4.2)                 | 0.1-8.3                     | 6/93 (6.5)                 | 1.4-11.5                    |
| Recurrent or multifocal tumors |                  |                             |                            |
| Surgeons 1-2            | 2/258 (0.8)                | 0-1.9                       | 23/255 (9.0)               | 5.5-12.6                    |
| Surgeons 4-5            | 5/137 (3.6)                | 0.5-6.8                     | 20/137 (14.6)              | 8.6-20.6                    |
| Recurrent and multifocal tumors |                        |                             |                            |
| Surgeons 1-2            | 0/129 (0)                  | –                           | 11/129 (8.5)               | 3.6-13.4                    |
| Surgeons 4-5            | 4/90 (4.4)                 | 0.1-8.8                     | 11/90 (12.2)               | 5.3-19.1                    |

CI – confidence interval, n – number of patients with recurrences, N – number of patients in the subgroup
initially staged as T1 [9]. However, there is some controversy in the current literature on the true significance of this criterion.

Mariappan et al. assessed the prognostic value of the presence of muscle tissue in the specimen after TURBT as a surrogate marker for the quality of the TURBT in a prospective database including 356 patients with NMIBC [4]. In the multivariate analysis, this parameter was associated with the resection of large, low-differentiated tumors and a senior surgeon that was defined as having 5 or more years of training. The early recurrence rate correlated with the absence of muscle in the specimen and a junior surgeon (odds ratio 2.9; 95% CI 1.6–5.4; p = 0.0002). In a similar study, Huang et al. found that the absence of muscle in the specimen after TURBT was more often observed with large tumors, tumors with difficult location and “young” surgeons (≤10 years of training) [10]. These factors, together with the absence of muscle in the specimen and T1 staging, were associated with the presence of residual tumor on repeat TURBT.

Rouprêt et al. evaluated the results of 340 TURBTs for pT1 NMIBC and found significant differences in the rate of muscle tissue detection in the specimen between junior and senior surgeons (61.3% vs. 73.8%; p = 0.02) [11]. However, in the multivariate analysis, only a junior surgeon as an operator, regardless of the presence or absence of the muscle tissue in the specimen, was predictive of recurrence (HR 2.33; 95% CI 1.45–3.74; p = 0.01). And finally, Shoshani et al., in the analysis of the data from 332 patients with NMIBC, found the association between the presence of muscle tissue in the specimen and high tumor grade, large size, multifocality and nonpapillary morphology, but not with the surgical experience [12]. Moreover, the lack of muscle tissue in the specimen had no effect on the long-term recurrence and progression rate in the overall patients’ cohort. Therefore, the authors concluded that the

Figure 4. Recurrence-free survival by length of TURBT experience (<10 vs. ≥10 years) among the most (A) and least successful (B) surgeons.
presence of muscle in the specimen was determined more by the tumor extent than by the surgeon’s experience, and the presence of muscle in the specimen can be a criterion of TURBT quality only in the T1 tumor subgroup. Unfortunately, we were unable to evaluate the presence of the muscle tissue in the TURBT specimen in our cohort as this criterion has not been systematically assessed in a significant number of patients. However, we would like to focus the attention on a more relevant and direct measurement of the TURBT quality by evaluating the 12-month recurrence rate, which we found to be the most discriminative between more and less successful surgeons. A single institution study and a low number of surgeons could not allow us to provide firm recommendations on optimal cut-off values of these parameters. We suggest conducting a multi-institution prospective study for assessing the early recurrence rate as a surrogate marker for the quality of TURBT in patients with NMIBC.

Finally, we have to underscore a wide variation in recurrence risk between different surgeons in our study reaching up to 1.71, which is more than HR for multiple or large tumors in a pivotal EORTC prognostic study [13]. Whereas any comparative trial exploring new therapies in NMIBC used to be balanced for basic prognostic factors of the tumor, it is unusual to ensure balance of the study arms by the operating surgeon. However, this may introduce a significant bias in the results of the comparative trials in which one group may be operated on by better surgeons than the other with fewer recurrences mimicking an effect of additional interventions.

**CONCLUSIONS**

A surgeon has a significant impact on the risk of recurrence after curative treatment of patients with NMIBC, which should be taken into account while performing and evaluating the results of comparative studies in this field. In our study, a significant difference between the surgeons was observed despite relatively similar and extensive experience in bladder endoscopic surgery and practicing in a setting of one specialized center. These differences were less prominent in less extensive tumors. Early recurrence rate may be used as a criterion of the quality of the TURBT.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**References**

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 10/Jan/2016.

2. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56: 430-442.

3. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64: 639-653.

4. Mariappan P, Zachou A, Grigor KM, et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumor specimen is as surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010; 57: 843-849.

5. Jancke G, Rosell J, Johnsson S. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer. Scand J Urol. 2014; 48: 276-283.

6. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002; 41: 523-531.

7. Brausi M, Sylvester R, van der Meijden A, Kurth KH. Does the surgeon have an impact in the outcome of patients with Ta-T1 TCC of the bladder? Results of an EORTC quality control study on TURBT. Eur Urol. 2001; Suppl 5: 119.

8. Del Zingaro M, Bruno R, Nunzi E, Porena M, Mearini L. First transurethral resection (TUR) and second TUR in intermediate-high risk bladder cancer: impact of the surgeon’s volume on the recurrence and progression of primary bladder cancer. Minerva Urol Nefrol. 2016; 68: 194-203.

9. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999; 162: 74-76.

10. Huang J, Fu J, Zhan H, et al. Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue. Urol Int. 2012; 89: 319-325.

11. Rouprêt M, Yates DR, Varinot J, Phé V, Chartièr-Kastler E, Bitker MO, Campérat E. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol. 2012; 19: 6459-6464.

12. Shoshany O, Mano R, Margel D, et al. Presence of detrusor muscle in bladder tumor specimens—predictors and effect on outcome as a measure of resection quality. Urol Oncol. 2014; 32: 40.e17-40.e22.

13. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: 466-465.